Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MCL1 inhibitor GS-9716

An orally bioavailable inhibitor of the anti-apoptotic protein myeloid cell leukemia 1 (MCL1; induced myeloid leukemia cell differentiation protein; myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential antineoplastic activity. Upon oral administration, MCL1 inhibitor GS-9716 targets and binds to MCL1. This prevents the binding of MCL1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing MCL1. MCL1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Mcl-1 inhibitor GS-9716
myeloid cell leukemia 1 inhibitor GS-9716
Code name:GS 9716
GS-9716
GS9716
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search